Faulding receives tentative FDA Approval for Acyclovir injection.

ELIZABETH, N.J.--(BUSINESS WIRE)--April 11, 1997--

Seeks share of $74 million market for antiviral drug

Faulding Inc.'s wholly owned subsidiary, Faulding Pharmaceutical Co., has received tentative approval from the Food and Drug Administration to market acyclovir injection, the generic version of Zovirax(R) brand of acyclovir sodium sterile powder, which in 1996 had sales of approximately $74 million. Final FDA approval is expected upon expiration of the brand's patent on April 22.

Acyclovir injection contains acyclovir, an antiviral drug active against herpes viruses. "Our product is a sterile solution and does not require reconstitution with sterile water. In contrast, the brand product Zovirax(R) must first be dissolved in sterile water prior to use, an extra step to be performed by the health care provider," explained Richard F. Moldin, president and chief executive officer of Faulding Inc.

The acyclovir injection approval is the fifth FDA approval received by Faulding Inc. this calendar year. Since January 1, Faulding Inc. has announced approvals for etodolac tablets and preserved and unpreserved presentations of atracurium besylate injection. On March 31 Purepac received FDA approval to market captopril tablets, a product that is not scheduled for commercial launch at this time due to extreme erosion in the market price for that product.

Faulding Inc. develops, manufactures, and markets human pharmaceuticals and medical devices. The shares of Faulding Inc. are traded on NASDAQ under the symbol "FAUL."

Note: Zovirax(R) is a registered trademark of Glaxo Wellcome.

CONTACT: Faulding Inc.

Andrew M. Berdon, 908/527-9100